ALK-Abello A/S
CSE:ALK B

Watchlist Manager
ALK-Abello A/S Logo
ALK-Abello A/S
CSE:ALK B
Watchlist
Price: 181 DKK -0.28% Market Closed
Market Cap: 36.7B DKK

Relative Value

The Relative Value of one ALK B stock under the Base Case scenario is 224.33 DKK. Compared to the current market price of 181 DKK, ALK-Abello A/S is Undervalued by 19%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALK B Relative Value
Base Case
224.33 DKK
Undervaluation 19%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
30
vs Industry
23
Median 3Y
6
Median 5Y
6.4
Industry
2.5
Forward
6.3
vs History
80
vs Industry
11
Median 3Y
50.4
Median 5Y
57.1
Industry
21.1
Forward
35.5
vs History
76
vs Industry
16
Median 3Y
39.9
Median 5Y
46.5
Industry
16.2
vs History
23
vs Industry
3
Median 3Y
84.7
Median 5Y
75.8
Industry
23.7
vs History
39
vs Industry
12
Median 3Y
6.3
Median 5Y
6.7
Industry
2.1
vs History
31
vs Industry
22
Median 3Y
6
Median 5Y
6.3
Industry
2.6
Forward
6.3
vs History
34
vs Industry
24
Median 3Y
9.5
Median 5Y
9.9
Industry
5.1
vs History
63
vs Industry
16
Median 3Y
27.5
Median 5Y
29.4
Industry
12.4
Forward
20.8
vs History
71
vs Industry
16
Median 3Y
36.7
Median 5Y
40.4
Industry
15.7
Forward
25.1
vs History
76
vs Industry
17
Median 3Y
40.8
Median 5Y
47
Industry
14.4
vs History
0
vs Industry
6
Median 3Y
173.6
Median 5Y
156.7
Industry
17.1
vs History
30
vs Industry
18
Median 3Y
4.5
Median 5Y
4.7
Industry
1.8

Multiples Across Competitors

ALK B Competitors Multiples
ALK-Abello A/S Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
ALK-Abello A/S
CSE:ALK B
40.1B DKK 7 42.8 26.3 32.2
US
Eli Lilly and Co
NYSE:LLY
722.9B USD 14.8 65.1 35 38.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
360.3B USD 4 16.5 12.1 15.9
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 7 20.2 14 16
CH
Roche Holding AG
SIX:ROG
206.2B CHF 3.4 24.9 9.4 11
CH
Novartis AG
SIX:NOVN
185.9B CHF 4.3 17.7 10.4 14
UK
AstraZeneca PLC
LSE:AZN
161.1B GBP 3.9 27.9 130.6 197
US
Merck & Co Inc
NYSE:MRK
198.9B USD 3.1 11.4 8.5 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
136.3B USD 2.2 17.3 7.4 10.5
P/E Multiple
Earnings Growth PEG
DK
ALK-Abello A/S
CSE:ALK B
Average P/E: 27.1
42.8
23%
1.9
US
Eli Lilly and Co
NYSE:LLY
65.1
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.5
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
18%
1.1
CH
Roche Holding AG
SIX:ROG
24.9
32%
0.8
CH
Novartis AG
SIX:NOVN
17.7
17%
1
UK
AstraZeneca PLC
LSE:AZN
27.9
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.4
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.3
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
ALK-Abello A/S
CSE:ALK B
Average EV/EBITDA: 396.5
26.3
21%
1.3
US
Eli Lilly and Co
NYSE:LLY
35
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.1
7%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
14
13%
1.1
CH
Roche Holding AG
SIX:ROG
9.4
5%
1.9
CH
Novartis AG
SIX:NOVN
10.4
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
130.6
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.5
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
2%
3.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
ALK-Abello A/S
CSE:ALK B
Average EV/EBIT: 1 700.2
32.2
23%
1.4
US
Eli Lilly and Co
NYSE:LLY
38.2
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
15.9
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
16
14%
1.1
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
14
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.3
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.5
10%
1